Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1093699

CNCc1cccc2ccccc12.Cl

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 1/20 0.53
IFNAR1 P17181 1/20 0.64
CYP1A2 P05177 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP2D6 P10635 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MC5R P33032 2/20 0.50
LMNA P02545 1/20 0.50
RECQL P46063 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP2C9 P11712 1/20 0.50
MAPK1 P28482 1/20 0.50
MC1R Q01726 1/20 0.49
HPGD P15428 1/20 0.49
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6251238 1.00 IFNAR1 (0.64) IFNAR1CA2CYP1A2CYP2C19CYP2D6
SCHEMBL681401 0.98 IFNAR1 (0.66) IFNAR1CA2CYP1A2CYP2C19CYP2D6
SCHEMBL29434746 0.98 IFNAR1 (0.66) IFNAR1CA2CYP1A2CYP2C19CYP2D6
SCHEMBL5321295 0.98 IFNAR1 (0.66) IFNAR1CA2CYP1A2CYP2C19CYP2D6
SCHEMBL14110952 0.84 IFNAR1 (0.51) IFNAR1CA2CYP1A2CYP2C19CYP2D6
Hydrochloric Acid SCHEMBL30725687 0.81 IFNAR1 (0.97) IFNAR1CYP1A2CYP2C19CYP2D6MEN1
Isophthalic Acid SCHEMBL27488646 0.81 POLB (0.54) IFNAR1MEN1KMT2ALMNARECQL
SCHEMBL6008064 0.80 MC5R (0.70) CA2CYP1A2CYP2C19CYP2D6MEN1
SCHEMBL3144929 0.80 IFNAR1 (0.51) IFNAR1CA2MEN1KMT2AMC5R
Hydrochloric Acid SCHEMBL27581438 0.80 MTNR1A (0.61) IFNAR1CYP1A2CYP2C19CYP2D6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112552182-B New synthesis process of naftifine drug intermediate N-methyl-1-naphthylmethylamine 杭州新桂实业有限公司 2022-10-11 CN claimed
CN-112552182-A New synthesis process of naftifine drug intermediate N-methyl-1-naphthylmethylamine 杭州新桂实业有限公司 2021-03-26 CN claimed
US-20200131431-A1 CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS ALCHEMY SCIENCES INC (US) 2020-04-30 US claimed
US-20060084826-A1 Process for the preparation of naphthylmethylamine derivatives GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-04-20 US claimed
CN-112552182-B New synthesis process of naftifine drug intermediate N-methyl-1-naphthylmethylamine 杭州新桂实业有限公司 2022-10-11 CN disclosed
CN-115073303-A Preparation method of terbinafine hydrochloride Z-type isomer 乐泰药业(兰西)有限公司 2022-09-20 CN disclosed
CN-111606811-B Preparation method of terbinafine hydrochloride 山东安弘制药有限公司 2022-09-06 CN disclosed
CN-114105774-A Preparation method of N-methyl-1-naphthylmethylamine 河北海力香料股份有限公司 2022-03-01 CN disclosed
CN-113788761-A Method and system for refining medical intermediate 丽江映华生物药业有限公司 2021-12-14 CN disclosed
CN-108164423-B Preparation method of naftifine hydrochloride 福建金山准点制药有限公司 2021-07-13 CN disclosed
CN-112552182-A New synthesis process of naftifine drug intermediate N-methyl-1-naphthylmethylamine 杭州新桂实业有限公司 2021-03-26 CN disclosed
CN-111606811-A Preparation method of terbinafine hydrochloride 山东安弘制药有限公司 2020-09-01 CN disclosed
US-6306959-B1 Rapid purification by polymer supported quench WARNER LAMBERT COMPANY 2001-10-23 US disclosed
WO-2000039055-A1 RAPID PURIFICATION BY POLYAROMATIC QUENCH REAGENTS WARNER-LAMBERT COMPANY (US) 2000-07-06 WO disclosed
EP-0896590-A1 RAPID PURIFICATION BY POLYMER SUPPORTED QUENCH WARNER-LAMBERT COMPANY (US) 1999-02-17 EP disclosed
US-5817875-A Methods for the manufacture of terbinafine KARIMIAN KHASHAYAR (CA) 1998-10-06 US disclosed
WO-1997042230-A1 RAPID PURIFICATION BY POLYMER SUPPORTED QUENCH WARNER-LAMBERT COMPANY (US) 1997-11-13 WO disclosed
US-4822822-A FUNGICIDES FOR PLANTS AND ANIMALS MITSUI TOATSU CHEMICALS, INC. (JP) 1989-04-18 US disclosed
EP-0221781-A2 Benzylamine derivatives, process for production thereof, and use thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1987-05-13 EP disclosed
US-4282251-A FUNGICIDES SANDOZ LTD. (CH) 1981-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084826-A1 Process for the preparation of naphthylmethylamine derivatives NAT1, NPM1, REN CA2 3932/4885IFNAR1 366/4885CYP1A2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.